Buyers of Zetia seek class recertification after 4th circ ruling
28-09-2021
France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck Group, genOway, licensing agreement, CRISPR/Cas9, genome editing, drug delivery, proprietary technology, research, genetically modified mice, rats
